On February 15, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co.) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
Read the FDA press release here.
Posted 2/19/2019
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
